Market Place
Sourcing Support
Ocuphire Initiates Ph 3 Trial of Phentolamine for Presbyopia
05 Sep 2024 //
GLOBENEWSWIRE
Ocuphire Pharma Announces Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
First Patient In LYNX-2 Phase 3 For Phentolamine After Eye Surgery
11 Apr 2024 //
GLOBENEWSWIRE
Viatris launches RYZUMVl 0.75% in US
02 Apr 2024 //
INDIANPHARMAPOST
Viatris and Ocuphire`s dilation eye drop Ryzumvi wins FDA nod
27 Sep 2023 //
FIERCE PHARMA
Enforcement Report - Week of January 18, 2023
18 Jan 2023 //
FDA
MD Pharmaceutical Supply, LLC Receives FDA Warning Letter
28 Dec 2022 //
FDA
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol NDA from FDA
12 Sep 2022 //
GLOBENEWSWIRE
Enforcement Report - Week Of June 01, 2022
01 Jun 2022 //
FDA
Enforcement Report - Week of March 23, 2022
23 Mar 2022 //
FDA
Enforcement Report - Week of November 17, 2021
17 Nov 2021 //
FDA
Enforcement Report - Week of March 11, 2020
12 Mar 2020 //
FDA
Enforcement Report - Week of January 22, 2020
22 Jan 2020 //
FDA
Ocuphire Pharma Announces Completion of the First of Two Ph2b Trials for Nyxol®
03 Sep 2019 //
BUSINESSWIRE
Enforcement Report - Week of July 17, 2019
17 Jul 2019 //
FDA
Enforcement Report - Week of June 19, 2019
19 Jun 2019 //
FDA
Enforcement Report - Week of May 8, 2019
08 May 2019 //
FDA
Enforcement Report - Week of November 7, 2018
07 Nov 2018 //
FDA
Enforcement Report - Week of August 22, 2018
22 Aug 2018 //
FDA
Enforcement Report - Week of May 16, 2018
16 May 2018 //
FDA
Health Canada Recalls OraVerse Injection
28 Apr 2018 //
HEALTH CANADA
Enforcement Report - Week of January 17, 2018
17 Jan 2018 //
FDA
Precision`s Generic Phentolamine mesylate Receives Approval In US
18 Jul 2017 //
FDA
US FDA Enforcement report- 13/Apr/2016
12 Apr 2016 //
FDA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.